While Eli Lilly
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Eli Lilly with 12 of 17 analysts rating it hold. Analysts don't like Eli Lilly as much as competitor Bristol-Myers Squibb overall. Fourteen out of 25 analysts rate Bristol-Myers Squibb a buy compared to two of 17 for Eli Lilly. Analysts still rate the stock a moderate sell, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $6.03 billion in revenue this quarter. That would represent a rise of 6.7% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $1.13 per share. Estimates range from $1.05 to $1.23.
What our community says:
CAPS All-Stars are solidly backing the stock with 95.4% giving it an "outperform" rating. The community at large concurs with the All-Stars with 93.5% awarding it a rating of "outperform." Fools are gung-ho about Eli Lilly and haven't been shy with their opinions lately, logging 411 posts in the past 30 days. Even with a robust four out of five stars, Eli Lilly's CAPS rating falls a little short of the community's upbeat outlook.
Eli Lilly's profit has risen year over year by an average of 9.9% over the past five quarters. Revenue has now gone up for three straight quarters.
For all our Eli Lilly-specific analysis, including earnings and beyond, add Eli Lilly to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.